Immunosuppression Clinical Trial
Official title:
Clinical Outcome of Dental Extractions Among Renal Transplant Recipients
The literature is rich in studies that explore the type and frequency of oral abnormalities in transplanted recipients, but it is scarce in studies that provide scientific evidence on the risk of complications after invasive interventions on those patients. Within this context, the aim of our study is to evaluate the post-exodontic socket healing in renal transplant recipients compared to a control group and see if some indicators in the population of transplanted people, such complete blood count, serum concentration of immunosuppressive drugs, can help to provide for the host response face a invasive procedures. Therefore, 45 kidney transplant recipients over six months and at least 45 healthy non immunosuppressed adults will be submitted to a maximum of 4 simple dental extractions, always by the same surgeon. Laboratory tests will be performed preoperatively and include: blood count and coagulation - for both groups - and urea, creatinine and serum levels of immunosuppressive drug - only for the study group. Researchers will evaluate the patient in the postoperative 3, 7, 21, and 60 days. The presence, or absence, of post-operative complication and delayed, or not, socket healing will be the results of interest in this study and will be compared between the groups. The data will be evaluated by Pearson's chi-square, Fisher's exact test, Mann-Whitney test, student's T-test and binomial test.
Investigators did not found scientific evidences neither evidence-based research, which
support the idea that stable kidney recipients have increased risk for delayed socket repair
and wound healing after exodontia or that infections resulted by oral surgery are more common
in these patients, despite the drug-induced immunosuppression which they use.
Since there is no scientific evidence about the increased risk of post-exodontic infection,
not even about a disorder on the alveolar repair chronology, after exodontia performed in
kidney recipients, the aim of our study will be prospectively observe kidney recipients who
are undergoing dental extractions.
This prospective cohort study will involve 45 adult kidney recipients for at least 6 months,
and 61 non-transplanted and healthy control adults, who need simple extraction of an erupted
tooth.
All the patients must be evaluated in the preoperative phase through anamnesis (e.g.
collecting data concerning on base diseases, personal history, presence of drug allergy,
medications in use, habits and addictions), extra-oral and intra-oral physical examinations
and laboratory tests.
Participants must sign the Inform and Clarified Consent Term to participate. Will be
disqualified participants that: used antibiotics in the month preceding the extraction, made
bisphosphonate therapy, user of illicit drugs, chronic alcoholics, who present with dental
emergencies, acute dental or periodontal infections, and patients with cognitive impairment.
One week before the dental extraction will be collected 15ml of blood from participants of
both group to perform complete blood count, coagulation tests, urea and creatinine
measurements. The serum measurement of the immunosuppressed drug will be performed only in
the individuals of study group.
Dental extractions, from one to three erupted teeth, will be performed by the same dentist,
specialist in Oral and Maxillofacial Surgery, enabled by the Federal Council of Dentistry, on
the ambulatory of CAPE (special care center) , under local anesthesia following the standards
described by Peterson et al (2003). The local anesthetic used in all individuals will be
prilocaine with epinephrine as vasoconstrictor. After the anesthetic blockade, incision and
mucosal detachment, luxation with elevators and tooth removal with forceps will be performed.
The surgical technique will be modified according the condition of the tooth on the socket;
when necessary tooth sectioning and/or ostectomy will be performed. By the end, curettage of
the socket, post-extraction alveolar compression to reduce the width of the same and simple
suture with 4.0 silk thread will be carried out.
Each tooth characteristics and each surgery data will be recorded and will include: surgical
duration (from the anesthesia to the suture), surgical technique variations, such the use of
elevators, forceps, mucoperiosteal flaps, tooth sectioning and/or ostectomy and
intraligamentary anesthesia, and number of anesthetics cartridges used.
After the surgery, the patient will press a gauze for 30 minutes in the extraction`s region
in order to control bleeding. It will be prescribed 750 mg of Acetominophen, up to 3 times a
day, for 24 hours. In case of necessity of change in the postoperative therapeutic due to
surgical technique variations, data will be recorded and included.
Clinical assessment of healing will be performed by a blinded examiner on 3, 7, 21 and 60
days after surgery. In these periods, the region will always be examined by the same
examiner.
Radiographic evaluation will be done with standardized periapical radiographs, with
individualized positioners, made in the immediately and 60 days postoperative, which bone
density and alveolar crest remodeling will be evaluated by a blinded examiner.
With 21 days postoperative, the socket will be classified as: 1) without complication; or 2)
with complications. According to Cheung et al (2001), the following situations will be
considered as post-exodontics complications:
Acute alveolar infection (dry socket, fibrinolytic osteitis, alveolar osteitis) or
surrounding tissue infection Acute alveolar inflammation.
In case of postoperatively infection, copious irrigation with sodium chloride solution (NaCl
0,9%) will be performed and will be prescribed amoxicilline 500 mg every 8 hours for 7 days
and anti-inflammatory nimesulide 100 mg every 12 hours for 5 days. In case of allergy to
penicillin, clindamycin will be prescribed at a dose of 300 mg every 8 hours for 7 days.
The second outcome of interest in this study will be observe the total alveolar
epithelialization. According to the literature, at 3 days postoperative, the socket is filled
with blood clot and fibrin; at 7 days, the socket is filled with granulation tissue; and from
21 days the surgical wound is fully epithelialized. Delayed epithelialization will be
considered in case at on the day 21, the socket would not yet fully covered by epithelialized
mucosa.
Finally, the third point will be the bone deposition in the socket, at 60 days postoperative.
All data will be transferred to an Excel spreadsheet and analyzed descriptively and
associated with each other. Complications will be compared between the two groups. In
addition, in the study group, researchers will investigate the occurrence of complications
associated with transplantation time, immunosuppressive dose, and presence of comorbidity,
such as diabetes.
Exact Fisher`s test or Fisher's exact test will be applied, Mann-Whitney`s test or Student's
T-test and binomial test using the R software, version 2.15.3 (R Development Core Team,
2012). The significance level will be set at 5%. Adjustments to modifying factors such as
smoking and presence of diabetes will be analyzed by logistic regression.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT01252537 -
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
|
N/A | |
Completed |
NCT00621699 -
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01678937 -
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
|
N/A | |
Completed |
NCT00788021 -
Protective Immunity Project 01
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT05616130 -
Pathological Myeloid Activation After Sepsis and Trauma
|
||
Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
Recruiting |
NCT01568697 -
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
|
||
Not yet recruiting |
NCT06024226 -
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
|
||
Not yet recruiting |
NCT04961229 -
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
|
Phase 4 | |
Completed |
NCT03139565 -
High Dose vs. Standard Influenza Vaccine in Adult SOT
|
Phase 3 | |
Completed |
NCT01702207 -
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
|
Phase 4 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00419575 -
Renal Transplantation With Immune Monitoring
|
N/A | |
Completed |
NCT00783380 -
Influenza Vaccination in Immunocompromized Patients
|
Phase 4 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Recruiting |
NCT05043870 -
Combined Immunosuppression for Pediatric Crohn's Disease
|
Phase 4 | |
Recruiting |
NCT05537948 -
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients
|
Phase 4 |